News from janssen research A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 12, 2014, 12:15 ET

Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium

 Janssen Research & Development, LLC (Janssen) today announced the presentation of data at the San Antonio Breast Cancer Symposium...

Dec 08, 2014, 21:33 ET

IMBRUVICA® (ibrutinib) Long-term Follow-up Data in Patients Living with Relapsed/Refractory Mantle Cell Lymphoma Show Almost Half Alive at Two Years

 New data presented today at the American Society of Hematology (ASH) Annual Meeting in San Francisco, CA, suggest the current safety and...

Dec 08, 2014, 21:05 ET

IMBRUVICA® (ibrutinib) Shows Sustained Progression-Free Survival in Patients with High-Risk Chronic Lymphocytic Leukemia with Genetic Mutation

Results from the Phase 2 RESONATE™-17 (PCYC-1117) study show IMBRUVICA® (ibrutinib) was associated with an 82.6 percent...

Nov 24, 2014, 16:30 ET

Janssen Submits New Drug Application for YONDELIS® (trabectedin) to U.S. FDA for the Treatment of Patients with Advanced Soft Tissue Sarcoma

 Janssen Research & Development, LLC (Janssen) has submitted a New Drug Application (NDA) for YONDELIS® (trabectedin) to the U.S. Food...

Nov 19, 2014, 09:00 ET

Janssen Submits New Drug Application to U.S. FDA for Three-Month Paliperidone Palmitate

Janssen Research & Development, LLC (Janssen) today announced the submission of a New Drug Application (NDA) for three-month atypical...

Nov 06, 2014, 09:54 ET

Janssen to Demonstrate Breadth of Oncology Portfolio with 41 Clinical Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting

Janssen Research & Development, LLC (Janssen) will present new data across more than eight disease areas at the 56th American Society of...

Nov 06, 2014, 03:00 ET

Janssen Collaborates for Continued Evaluation of Multidrug-Resistant Tuberculosis Treatment Regimens with SIRTURO® (bedaquiline)

Janssen Research & Development, LLC (Janssen) today announced a collaboration with the International Union Against Tuberculosis and Lung...

Oct 20, 2014, 08:05 ET

IMBRUVICA® (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom's macroglobulinemia

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for...

Sep 28, 2014, 07:00 ET

ZYTIGA® Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis in Chemotherapy-Naive Men with Metastatic Castration-Resistant Prostate Cancer

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain...

Aug 29, 2014, 10:10 ET

Janssen Expands EXPLORER Global Cardiovascular Research Program to Evaluate the Role of XARELTO® in Addressing Critical Medical Needs

 Janssen Research & Development, LLC (Janssen) and its development partner, Bayer HealthCare, announced today the expansion of the EXPLORER...

Aug 25, 2014, 08:00 ET

Data on XARELTO® at ESC Congress 2014 Hot Line Session Premieres First Prospective Study of a Factor Xa Inhibitor in Elective Cardioversion

 Janssen Research & Development, LLC (Janssen) announced today that results from the Phase 3b exploratory X-VeRT study, investigating the...

Aug 05, 2014, 09:00 ET

Janssen Launches Online Healthy Minds Video Series

Janssen Research & Development, LLC, today launched the first in a series of online videos addressing key mental health topics and treatments...

Jun 16, 2014, 17:00 ET

New Long-Term Data Show INVOKANA® (canagliflozin) Lowers Blood Glucose in Older Patients with Type 2 Diabetes Inadequately Controlled on Other Therapies

 Janssen Research & Development, LLC (Janssen) today announced new results from a 104-week Phase 3 clinical study evaluating the long-term...

Jun 10, 2014, 08:56 ET

Janssen to Present Latest Data for Type 2 Diabetes Treatment INVOKANA® (canagliflozin) at American Diabetes Association 74th Scientific Sessions®

 Janssen Research & Development, LLC (Janssen) announced today that 15 presentations on INVOKANA® (canagliflozin) will be made at the...

May 14, 2014, 17:12 ET

Janssen to Showcase Growing Body of Data at 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

Janssen Research & Development, LLC (Janssen) announced data related to seven compounds have been selected for presentation at the 50th Annual...

May 14, 2014, 08:00 ET
May 07, 2014, 07:45 ET
May 05, 2014, 08:00 ET

Innovative Public-Private Consortium Established To Define The Triggers Of Inflammatory Bowel Disease

 Janssen Research & Development, LLC (Janssen) announced today the establishment of a Cooperative Research and Development Agreement...

Apr 08, 2014, 08:06 ET

Supplemental New Drug Application for IMBRUVICA™ (ibrutinib) Submitted to the U.S. FDA

 Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for...

Apr 01, 2014, 07:45 ET

Janssen Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of HIV-1 Medicine Darunavir with Cobicistat as Part of Combination HIV Therapy

Janssen Research & Development, LLC (Janssen), today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug...